Professor of Medicine, UCSD
Internal Medicine
Dr. Lewis J. Rubin, MD
|
|
Give Review
Lewis Rubin works in the field of Internal Medicine. He went to Albert Einstein College of Medicine of Yeshiva University. He over the years received 1 awards: "Elected Member". Lewis J. Rubin is also a published doctor. He has 82 publication published. The most recent publication is: Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN.
Publications
- Incident and prevalent cohorts with Pulmonary arterial hypertension: insight from SERAPHIN.
- New horizons in Pulmonary arterial hypertension management.
- Two formulations of epoprostenol sodium in the treatment of Pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in Pulmonary arterial hypertension),...
- Long-term sildenafil added to intravenous epoprostenol in patients with Pulmonary arterial hypertension.
- Long-term results from the EARLY study of bosentan in WHO functional class II Pulmonary arterial hypertension patients.
- A paradigm shift in Pulmonary arterial hypertension management.
- New trial designs and potential therapies for Pulmonary artery hypertension.
- Cor pulmonale revisited.
- Treatment of Pulmonary Hypertension Caused by Left Heart Failure With Pulmonary Arterial Hypertension-Specific Therapies: Lessons From the Right and LEPHT.
- Robyn J. Barst, MD.
- Reduction of Pulmonary arterial hypertension (pah)-related hospitalizations with macitentan in the randomized controlled trial seraphin.
- Contemporary trends in the diagnosis and management of Pulmonary arterial hypertension: an initiative to close the care gap.
- Rapid transition from inhaled iloprost to inhaled treprostinil in patients with Pulmonary arterial hypertension.
- Pulmonary arterial hypertension: bridging the present to the future.
- Endothelin receptor antagonists for the treatment of Pulmonary artery hypertension.
- Safety and Efficacy of Transition from Systemic Prostanoids to Inhaled Treprostinil in Pulmonary Arterial Hypertension.
- Exercise training for Pulmonary hypertension: another prescription to write?
- Combination Therapy for Pulmonary Artery Hypertension: What Is the Evidence?
- Long-term effects of inhaled treprostinil in patients with Pulmonary arterial hypertension: The TReprostinil sodium Inhalation Used in the Management of Pulmonary arte...
- Analysis of the Validation Status of Quality of Life and Functional Disability Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis: Results of a ...
- Systemic sclerosis-associated Pulmonary hypertension: why disease-specific composite endpoints are needed.
- Metabolic dysfunction in the pathogenesis of Pulmonary hypertension.
- Editor's response to "ethical issues associated with globalization of placebo-controlled trials in Pulmonary arterial hypertension".
- Worldwide physician education and training in Pulmonary hypertension: Pulmonary vascular disease: the global perspective.
- Addition of inhaled treprostinil to oral therapy for Pulmonary arterial hypertension: a randomized controlled clinical trial.
- Phosphodiesterase inhibitors for Pulmonary hypertension.
- The globalization of clinical trials in Pulmonary arterial hypertension.
- Borderline Pulmonary arterial pressure is associated with decreased exercise capacity in scleroderma.
- Medical treatment of Pulmonary arterial hypertension.
- Future perspectives for the treatment of Pulmonary arterial hypertension.
- Updated evidence-based treatment algorithm in Pulmonary arterial hypertension.
- Identification of putative endothelial progenitor cells (CD34+CD133+Flk-1+) in endarterectomized tissue of patients with chronic thromboembolic Pulmonary hypertension.
- A functional single-nucleotide polymorphism in the TRPC6 gene promoter associated with idiopathic Pulmonary arterial hypertension.
- Endothelin and the systemic circulation a therapeutic target worth revisiting?
- Hemodynamics and epoprostenol use are associated with thrombocytopenia in Pulmonary arterial hypertension.
- Ambrisentan therapy in patients with Pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities.
- Exercise-induced Pulmonary arterial hypertension: a new addition to the spectrum of Pulmonary vascular diseases.
- Prednisolone inhibits PDGF-induced nuclear translocation of NF-kappaB in human Pulmonary artery smooth muscle cells.
- Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with Pulmonary arterial hypertension: a randomized trial.
- BMPR2 mutation and outcome in Pulmonary arterial hypertension: clinical relevance to physicians and patients.
- Treatment of Pulmonary arterial hypertension due to scleroderma: challenges for the future.
- Central venous blood oxygen saturation monitoring in patients with chronic Pulmonary arterial hypertension treated with continuous IV epoprostenol: correlation with me...
- Hemodynamic and functional assessment of patients with sickle cell disease and Pulmonary hypertension.
- Medical therapy for Pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines.
- Upregulation of Na+/Ca2+ exchanger contributes to the enhanced Ca2+ entry in Pulmonary artery smooth muscle cells from patients with idiopathic Pulmonary arterial hype...
- Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic Pulmonary arterial hypertension.
- Complications of right heart catheterization procedures in patients with Pulmonary hypertension in experienced centers.
- Randomized study of adding inhaled iloprost to existing bosentan in Pulmonary arterial hypertension.
- Is methamphetamine use associated with idiopathic Pulmonary arterial hypertension?
- Favorable effects of inhaled treprostinil in severe Pulmonary hypertension: results from randomized controlled pilot studies.
- Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in Pulmonary arterial hypertension.
- Endothelin-1 and the Pulmonary vascular response to altitude: a new therapeutic target?
- Temporal trends and drug exposures in Pulmonary hypertension: an American experience.
- Current and future management of chronic thromboembolic Pulmonary hypertension: from diagnosis to treatment responses.
- Update in Pulmonary hypertension 2005.
- Management following Pulmonary thromboendarterectomy: experience versus evidence.
- Evaluation and management of the patient with Pulmonary arterial hypertension.
- Ambrisentan therapy for Pulmonary arterial hypertension.
- Epoprostenol and nesiritide in Pulmonary hypertension.
- Pathogenesis of Pulmonary arterial hypertension: the need for multiple hits.
- Bosentan inhibits transient receptor potential channel expression in Pulmonary vascular myocytes.
- Enhanced expression of transient receptor potential channels in idiopathic Pulmonary arterial hypertension.
- Cellular and molecular mechanisms of Pulmonary vascular remodeling: role in the development of Pulmonary hypertension.
- Sildenafil for enhanced performance at high altitude?
- Mars or venus--is sex a risk factor for recurrent venous thromboembolism?
- Pulmonary arterial hypertension: a look to the future.
- Comparative analysis of clinical trials and evidence-based treatment algorithm in Pulmonary arterial hypertension.
- Endothelin receptor antagonists in Pulmonary arterial hypertension.
- Clinical classification of Pulmonary hypertension.
- Preoperative partitioning of Pulmonary vascular resistance correlates with early outcome after thromboendarterectomy for chronic thromboembolic Pulmonary hypertension.
- Successful withdrawal of long-term epoprostenol therapy for Pulmonary arterial hypertension.
- Bone morphogenetic proteins induce apoptosis in human Pulmonary vascular smooth muscle cells.
- Effects of the dual endothelin receptor antagonist bosentan in patients with Pulmonary arterial hypertension: a 1-year follow-up study.
- Epoprostenol therapy as a bridge to Pulmonary thromboendarterectomy for chronic thromboembolic Pulmonary hypertension.
- Therapy of Pulmonary hypertension: the evolution from vasodilators to antiproliferative agents.
- New treatments for Pulmonary arterial hypertension.
- Bosentan therapy for Pulmonary arterial hypertension.
- Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human Pulmonary artery.
- Nitric oxide induces apoptosis by activating K+ channels in Pulmonary vascular smooth muscle cells.
- Endothelin in health and disease: endothelin receptor antagonists in the management of Pulmonary artery hypertension.
- Pulmonary Hypertension: Current Management and Future Directions.
Schools
Albert Einstein College of Medicine of Yeshiva University
Duke University Med Center
Conditions Treated
- Pulmonary Hypertension
Doctors Specialties
- Critical Care Medicine
- Pulmonology
- Internal Medicine
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- Blue Cross Blue Shield of California PPO
- First Health (Coventry Health Care) PPO
- Medicare MCR
- Kaiser PHCS Network PPO
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- PacifiCare HMO
Awards
- Elected Member
Education
-
Duke University Hospital -
Albert Einstein College of Medicine of Yeshiva University
Hospital
-
UC San Diego Health
Helpful Reviews
Similar Doctors
|
|
Dr. Bhupinder S. Khehar, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bernard J. Lichtenstein, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anna Gelberg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas V. McAfee, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Larry I. Emdur, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edward C. Federman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Oleg Y. Sorokoumov, MD |
|
|
Dr. Richard S. Sacks, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark M. Fuster, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shannon Y. Moore, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brian W. Mecklenburg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Howard M. Worthen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David M. Levine, MD
This Doctor is OpenDoctor Recommended.
|